事件： 近期宠物行业相关公司如乖宝宠物、中宠股份、佩蒂股份等股价有所回调，依依股份股价表现相对较 强。 点评： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 农林牧渔行业 超配（维持） 国内市场仍有扩容空间 国产龙头仍有增长动力 宠物行业跟踪点评 2025 年 7 月 23 日 分析师：魏红梅（SAC 执业证书编号：S0340513040002） 电话：0769-22119462 邮箱：whm2@dgzq.com.cn 跟 踪 点 评 行 证券研究报告风险等级及适当性匹配关系 | 低风险 | 宏观经济及政策、财经资讯、国债等方面的研究报告 | | --- | --- | | 中低风险 | 债券、货币市场基金、债券基金等方面的研究报告 | | 中风险 | 主板股票及基金、可转债等方面的研究报告，市场策略研究报告 | | 中高风险 | 创业板、科创板、北京证券交易所、新三板（含退市整理期）等板块的股票、基金、可转债等 | | | 方面的研究报告，港股股票、基金研究报告以及非上市公司的研究报告 | | 高风险 | ...

内容概要：兽药原料药是指具有药理活性、直接用于制造兽药制剂的化学或生物物质，是兽药的有效成 分。自改革开放以来，我国畜牧业发展取得了举世瞩目的成就。在畜牧业发展中，兽药产业的贡献不可 磨灭。兽药原料药作为兽药生产的关键原料，被称为兽药制剂中的"芯片"，处于兽药产业链核心环节， 在兽药行业中占据着重要地位。随着我国养殖行业疾病防护意识不断加强，兽药原料药需求迅速增长。 2024年中国兽药原料药市场规模约185.1亿元，2025年，在宽松的货币和财政政策下，经济大环境有望 进一步好转，需求的进一步复苏和供应端的持续控制，兽药原料药市场整体表现或将好于2024年。预计 2025年中国兽药原料药市场规模约为200亿元。从细分市场来看，在我国兽药原料药中，抗微生物药在 兽药原料药市场中占据绝对主导地位，占据兽药原料药84%的市场份额，占比长期居于首位；寄生虫药 约占11%的市场份额。 上市企业：海昇药业[870656]、国邦医药[605507]、普洛药业[000739]、宏源药业[301246]、瑞普生物 [300119]、金河生物[002688]、生物股份[600201]、绿康生化、天康生物[002100]、*ST绿 ...

Group 1 - Senyuan Electric signed a strategic cooperation agreement with Xuchang Digital Supply Chain Management Co., aiming for annual business cooperation not exceeding 500 million yuan over 36 months [1] - CICC's subsidiary, CICC Wealth, reported a net profit of 987 million yuan for the first half of the year, with total assets of 193.37 billion yuan [2] - Shuangjie Electric expects a net profit of 100 million to 120 million yuan for the first half of the year, representing a year-on-year increase of 16.03% to 39.23% [3][4] - Shentong Technology reported a net profit of 64.28 million yuan for the first half of the year, a year-on-year increase of 111.09% [5] - Suqian Nongfa's net profit for the first half of the year decreased by 27.72% to 213 million yuan [6] Group 2 - Fuan Pharmaceutical expects a net profit decline of 39.95% to 53.81% for the first half of the year, estimating between 100 million to 130 million yuan [8] - Xingwang Yuda anticipates a net loss of 11 million to 21 million yuan for the first half of the year [9] - Pulaike received a new veterinary drug registration certificate for a vaccine aimed at preventing chicken diseases [10] - Yuandong Biological's ephedrine injection received a drug registration certificate for treating low blood pressure during anesthesia [11] - Suqian Liansheng's subsidiary obtained two invention patent certificates [12] Group 3 - Oke Technology signed a 176 million yuan equipment order with Jiangxi Tianhong New Materials [13] - Publishing Media announced the resignation of its chief accountant due to work changes [15] - Zhongxin Co. plans to use 40 million yuan of idle funds for cash management [16] - Huiyun Titanium plans to use up to 58 million yuan of idle convertible bond funds for cash management [18] - Haineng Technology intends to apply for a credit facility of up to 200 million yuan from a bank [20] Group 4 - Jiabiou expects a net profit increase of 57.61% for the first half of the year, estimating around 107 million yuan [21] - Nanjing Gaoke reported a 1185% year-on-year increase in contract sales area for the second quarter [22] - Shuguang Co. received approval for a specific stock issuance application [23] - Huadong Pharmaceutical's subsidiary received approval for a clinical trial of a new drug targeting advanced solid tumors [23] - Quicheng Co. plans to invest 900 million yuan in two new projects [25] Group 5 - Shenlian Biological's vaccine for avian adenovirus received a new veterinary drug registration certificate [26] - Rike Chemical signed a strategic cooperation framework agreement with Dongming Petrochemical [28] - Jincheng Pharmaceutical's subsidiary received a renewed tobacco production license [29] - Magmi Te's stock issuance application was accepted by the Shenzhen Stock Exchange [29] - Zhongyin Securities received approval to issue bonds totaling up to 14 billion yuan [29] Group 6 - Hewei Electric's executives plan to reduce their holdings by a total of 2.24% of the company's shares [44] - Guo Wang Xintong reported a net profit of 266 million yuan for the first half of the year, a decrease of 10.82% [45] - Guo Wang Xintong's subsidiary won a 966 million yuan tender from the State Grid [46] - Jicheng Electronics won contracts worth approximately 83.79 million yuan from the State Grid [48] - Helen Piano is planning a change of control, leading to a temporary stock suspension [48]

农林牧渔 zhangmz@ccnew.com 13681931564 市场需求疲软，畜禽价格低迷 ——农林牧渔行业月报 证券研究报告-行业月报 强于大市(维持) 《农林牧渔行业月报：畜禽价格低迷，宠物 食品 618 消费表现亮眼》 2025-06-23 《农林牧渔行业半年度策略：周期掘金，向 新而行》 2025-06-18 《农林牧渔行业月报：指数表现强势，宠物 出口数据维持快速增长》 2025-05-20 联系人：李智 投资要点： 风险提示：畜禽价格大幅波动，粮价大幅波动，动物疫病的发生；我 国生物育种商业化应用不及预期；食品安全问题，自然灾害事件。 本报告版权属于中原证券股份有限公司 www.ccnew.com 请阅读最后一页各项声明 第1页 / 共15页 盈利预测和投资评级 | 公司简称 | 24EPS 25EPS | | 25PE | 评级 | | --- | --- | --- | --- | --- | | 牧原股份 | 3.30 | 3.76 | 10.26 | 增持 | | 普莱柯 | 0.27 | 0.52 | 26.60 | 增持 | | 秋乐种业 | 0.31 | 0.33 | 58.8 ...

注册分类：三类 主要成分：疫苗中含鸡新城疫病毒 La Sota 株≥10 6.0EID50/羽份；含鸡传染性 支气管炎病毒 SZ160 株≥10 3.5EID50/羽份。 作用与用途：用于预防鸡新城疫和鸡传染性支气管炎。接种后 7 日产生免疫 力，免疫期为 3 个月。 证券代码：603566 证券简称：普莱柯 公告编号：2025-028 普莱柯生物工程股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）与其他单位联合申报的"鸡 新城疫、传染性支气管炎二联耐热保护剂活疫苗（La Sota 株+SZ160 株）"为新 兽药，并于 2025 年 7 月 17 日公示了核发《新兽药注册证书》（中华人民共和国 农业农村部公告第 930 号）事项。详情如下： 一、新兽药的基本信息 新兽药名称：鸡新城疫、传染性支气管炎二联耐热保护剂活疫苗（La Sota 株+SZ160 株） 经查询国家兽 ...

普莱柯：公司获得新兽药注册证书 智通财经7月18日电，普莱柯(603566.SH)公告称，公司与其他单位联合申报的"鸡新城疫、传染性支气 管炎二联耐热保护剂活疫苗（LaSota株+SZ160株）"为新兽药，并于2025年7月17日公示了核发《新兽 药注册证书》。该新兽药采用的毒株SZ160株为流行QX型毒株的驯化致弱株，具有高繁殖性能、高安 全性、快速免疫起效和长免疫持续期等特点，可有效防控目前国内流行的鸡传染性支气管炎疫病。该产 品上市将丰富公司禽用疫苗产品品类，提升市场竞争力，并为公司带来新的业绩增长点。 ...

Group 1: Industry Overview - The animal vaccine sector has seen a significant rise, with a market increase of approximately 2.91% as of July 16, 2023 [1] - The animal vaccine market is divided into two main categories: pet vaccines and livestock vaccines [1] - The pet vaccine market is experiencing rapid growth, driven by an increase in pet ownership and rising consumer spending, with the market size expected to exceed 345.3 billion yuan in 2024 [1] - The penetration rate of pet vaccines remains low, indicating substantial growth potential as pet owners become more health-conscious [1] Group 2: Livestock Vaccine Insights - In the context of the current "anti-involution" trend in pig farming, about 30% of pig companies have achieved over 50% of their annual output targets [2] - Major pig companies are implementing policies such as reducing breeding sows and controlling weight to enhance efficiency and disease prevention [2] - The demand for vaccines is expected to grow steadily alongside the development of the livestock industry, particularly due to the need for disease control against outbreaks like African swine fever [2] Group 3: Company Profiles - **Shengwu Co., Ltd.**: Focuses on the research, production, and sales of veterinary biological products, including vaccines for pigs, ruminants, poultry, and pets [2] - **Reap Bio**: A high-tech enterprise dedicated to providing solutions for disease prevention, treatment, and healthy breeding in the animal health industry [2] - **Kexing Pharmaceutical**: Engaged in animal vaccine research and development with a focus on zoonotic disease prevention [3] - **Puleke**: Specializes in the research, production, and sales of veterinary biological products and chemical drugs [4] - **Zhongmu Co., Ltd.**: Offers a wide range of vaccines, including poultry, veterinary, and special vaccines, with nearly 170 varieties [4] - **Shenlian Bio**: Primarily involved in the research, production, and sales of veterinary biological products, with pig vaccines as a major revenue source [4] - **Haizheng Pharmaceutical**: Its subsidiary focuses on the research, production, and sales of veterinary biological drugs [5] - **Haili Bio**: Engages in the research, production, and sales of animal vaccines [6]

Group 1 - The A-share animal vaccine sector experienced a significant rally, with Bio-Pharmaceuticals hitting the daily limit up [1] - Other companies such as Sinovac Biotech, Luoyang Agricultural, China Animal Husbandry, and Prilaco also saw increases in their stock prices [1]

Group 1 - The article discusses the recent market performance, indicating that the Shanghai Composite Index has stabilized around 3500 points, driven by policy expectations and potential government stimulus measures [1][2] - Analysts from Citigroup predict that the upcoming Politburo meeting will not revise the budget or increase government bond quotas, but will focus on implementing existing policies to support consumption and the real estate sector [1][2] - The article highlights that the real estate market has shown signs of recovery, with a potential for further gains in the coming weeks, based on historical trends of policy-driven market movements [3][5] Group 2 - The banking sector is expected to see an increase in dividend yields due to upcoming dividend distributions, which could enhance the attractiveness of bank stocks [7] - The article notes that the insurance sector is adjusting its investment strategies to favor high-dividend assets, which may impact the overall market dynamics [7] - The article mentions that the real estate index has risen by 9.69% since June 23, indicating a positive trend relative to the Shanghai Composite Index [3][5] Group 3 - The article outlines the upcoming key events in the financial calendar, including the Politburo meeting and FOMC meetings, which are expected to influence market sentiment and policy direction [2] - It emphasizes the importance of monitoring economic indicators and policy announcements as they could significantly impact market performance in the second half of the year [2][10] - The article suggests that sectors such as renewable energy, construction materials, and industrial metals are likely to benefit from current market trends and policy support [15][18]

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., forecasts a significant increase in net profit for the first half of 2025, driven by new product launches and strong sales in pet-related products [1][4]. Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 107 million yuan and 122 million yuan, representing a year-on-year increase of 44.70% to 64.98% [2][4]. - The forecasted net profit, excluding non-recurring gains and losses, is anticipated to be between 93 million yuan and 106 million yuan, reflecting a year-on-year increase of 40.05% to 59.63% [2][4]. Previous Year Performance - In the same period last year, the net profit attributable to shareholders was 73.9463 million yuan, and the net profit after excluding non-recurring gains and losses was 66.4035 million yuan [2]. Reasons for Performance Increase - The launch of new products, such as the joint vaccine, has contributed to new growth points for the company. Sales revenue from pet-related products continues to show high growth [2]. - The company is focusing on marketing system reform, strengthening process management, and ensuring performance implementation to meet sales targets amid intense market competition [2]. - Lean production management has optimized unit costs, and enhanced control over sales expenses has been implemented to achieve high-quality and efficient development goals [2].